| __timestamp | Amphastar Pharmaceuticals, Inc. | Cytokinetics, Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 159205000 | 44426000 |
| Thursday, January 1, 2015 | 174172000 | 46398000 |
| Friday, January 1, 2016 | 150976000 | 59897000 |
| Sunday, January 1, 2017 | 149380000 | 90296000 |
| Monday, January 1, 2018 | 187681000 | 89135000 |
| Tuesday, January 1, 2019 | 190434000 | 86125000 |
| Wednesday, January 1, 2020 | 206506000 | 96951000 |
| Friday, January 1, 2021 | 238029000 | 159938000 |
| Saturday, January 1, 2022 | 250127000 | 240813000 |
| Sunday, January 1, 2023 | 293274000 | 330123000 |
Unleashing insights
In the ever-evolving landscape of biopharmaceuticals, understanding cost dynamics is crucial. Amphastar Pharmaceuticals, Inc. and Cytokinetics, Incorporated have shown distinct financial trajectories from 2014 to 2023. Amphastar's cost of revenue has surged by approximately 84%, reflecting its expanding operations and market reach. Meanwhile, Cytokinetics has experienced a staggering 643% increase, indicating significant growth and investment in research and development.
Amphastar's steady rise in costs, peaking at nearly $293 million in 2023, underscores its strategic expansion. In contrast, Cytokinetics' costs, which started at a modest $44 million in 2014, have ballooned to over $330 million, highlighting its aggressive push into new therapeutic areas. This financial narrative not only showcases the companies' growth but also mirrors the broader trends in the biopharma sector, where innovation and expansion drive cost dynamics.
Cost of Revenue Trends: AstraZeneca PLC vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Cytokinetics, Incorporated
Analyzing Cost of Revenue: Viatris Inc. and Cytokinetics, Incorporated
Cost of Revenue: Key Insights for Walgreens Boots Alliance, Inc. and Cytokinetics, Incorporated
Cost of Revenue Trends: Halozyme Therapeutics, Inc. vs Cytokinetics, Incorporated
Analyzing Cost of Revenue: Lantheus Holdings, Inc. and Amphastar Pharmaceuticals, Inc.
Grifols, S.A. vs Cytokinetics, Incorporated: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Cytokinetics, Incorporated vs Agios Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Cytokinetics, Incorporated and Supernus Pharmaceuticals, Inc.
Cytokinetics, Incorporated vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.